These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15449634)

  • 1. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
    Crott R; Ali F; Burdette-Radoux S
    Value Health; 2004; 7(4):423-32. PubMed ID: 15449634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review.
    Crott R
    Pharmacoeconomics; 2004; 22(9):569-80. PubMed ID: 15209526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma.
    Wilson LS; Reyes CM; Lu C; Lu M; Yen C
    Melanoma Res; 2002 Dec; 12(6):607-17. PubMed ID: 12459651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.
    Hillner BE; Kirkwood JM; Atkins MB; Johnson ER; Smith TJ
    J Clin Oncol; 1997 Jun; 15(6):2351-8. PubMed ID: 9196150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.
    Dixon S; Walters SJ; Turner L; Hancock BW
    Br J Cancer; 2006 Feb; 94(4):492-8. PubMed ID: 16449995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.
    González-Larriba JL; Serrano S; Alvarez-Mon M; Camacho F; Casado MA; Díaz-Pérez JL; Díaz-Rubio E; Fosbrook L; Guillem V; López-López JJ; Moreno-Nogueira JA; Toribio J
    Eur J Cancer; 2000 Dec; 36(18):2344-52. PubMed ID: 11094308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma.
    Lafuma A; Dreno B; Delaunay M; Emery C; Fagnani F; Hieke K; Bonerandi JJ; Grob JJ;
    Eur J Cancer; 2001 Feb; 37(3):369-75. PubMed ID: 11239759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.
    Hillner BE
    Eur J Cancer; 1998 Jul; 34 Suppl 3():S18-21. PubMed ID: 9849404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who benefits most from adjuvant interferon treatment for melanoma?
    Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
    Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
    Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
    J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on adjuvant interferon therapy for high-risk melanoma.
    Agarwala SS; Kirkwood JM
    Oncology (Williston Park); 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197. PubMed ID: 12380946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.
    Kirkwood JM; Ibrahim JG; Sondak VK; Richards J; Flaherty LE; Ernstoff MS; Smith TJ; Rao U; Steele M; Blum RH
    J Clin Oncol; 2000 Jun; 18(12):2444-58. PubMed ID: 10856105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
    J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.